mesotherapy ghk cu clinical trial GHK-Cu vs NAD+: Which Longevity Peptide Should You Take or Stack? Injectable Peptides for Anti-Aging? A

Cell Reports (2018) 10.1016/j.celrep.2018.05.054 Follow-up study showing that p53 mutations (common in cancer cells) confer resistance to FOXO4-DRI, highlighting the p53-dependent mechanism and the importance of functional p53 for the senolytic effect

The peptide demonstrates resistance to pepsin (gastric protease), trypsin and chymotrypsin (pancreatic serine proteases), and various intestinal peptidases

Major employers include ProMedica, Owens Corning, and automotive suppliers

Shih, D

Similarly, a pilot study in 2015, a clinical trial (randomised) on 42 healthy human participants, receiving oral (tablet form) dosages of BPC 157 was carried out (Clinicaltrials.gov 2018): 0.25, 0.5, 1 and 2 g/kg